Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J
Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Eur Urol. 1993;24(1):156-60. doi: 10.1159/000474284.
The expression of the multidrug-resistance gene product, P-glycoprotein was examined immunohistochemically in 31 untreated human renal cell carcinomas. In 17 of these, chemosensitivity to Adriamycin and vinblastine was also assessed by a microtiter succinate dehydrogenase inhibition test and the correlation between the expression of P-glycoprotein and intrinsic multidrug resistance was investigated. P-glycoprotein was detected in 16 (51.6%) of the 31 carcinomas. In the chemosensitivity test, 14 (82.4%) of the 17 carcinomas were estimated to be resistant to both drugs (multidrug resistant; MDR). Eight (72.7%) of the 11 carcinomas with a positive expression of P-glycoprotein were MDR, and none of them were sensitive of both drugs. On the other hand, MDR carcinomas were not necessarily associated with the expression of P-glycoprotein. Eight (61.5%) of the 13 MDR carcinomas showed a positive expression of P-glycoprotein while the remaining 5 (38.5%) were negative. These results suggest that the expression of P-glycoprotein is an important factor responsible for the intrinsic MDR phenotype of renal cell carcinoma, however, there are probably other factors involved as well which have yet to be fully elucidated.
采用免疫组织化学方法检测了31例未经治疗的人肾细胞癌中多药耐药基因产物P-糖蛋白的表达情况。其中17例还通过微量滴定板琥珀酸脱氢酶抑制试验评估了对阿霉素和长春碱的化学敏感性，并研究了P-糖蛋白表达与内在多药耐药性之间的相关性。在31例癌组织中，有16例（51.6%）检测到P-糖蛋白。在化学敏感性试验中，17例癌组织中有14例（82.4%）被估计对两种药物均耐药（多药耐药；MDR）。P-糖蛋白表达阳性的11例癌组织中有8例（72.7%）为MDR，且无一例对两种药物敏感。另一方面，MDR癌组织不一定与P-糖蛋白的表达相关。13例MDR癌组织中有8例（61.5%）P-糖蛋白表达阳性，其余5例（38.5%）为阴性。这些结果表明，P-糖蛋白的表达是肾细胞癌内在MDR表型的一个重要因素，然而，可能还涉及其他尚未完全阐明的因素。
